Vaxcyte (NASDAQ:PCVX) Announces Quarterly Earnings Results

Vaxcyte (NASDAQ:PCVX) issued its quarterly earnings data on Tuesday. The company reported ($1.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14, Zacks reports.

Vaxcyte Price Performance

NASDAQ:PCVX opened at $79.35 on Wednesday. Vaxcyte has a 1-year low of $58.10 and a 1-year high of $121.06. The company has a market capitalization of $9.89 billion, a PE ratio of -17.25 and a beta of 0.98. The firm’s 50-day moving average price is $85.25 and its 200-day moving average price is $95.00.

Insider Buying and Selling

In other news, CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $92.45, for a total transaction of $1,386,750.00. Following the completion of the transaction, the chief executive officer now directly owns 450,301 shares in the company, valued at approximately $41,630,327.45. This trade represents a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jim Wassil sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total value of $669,280.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at approximately $17,208,443.70. This represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 76,616 shares of company stock valued at $6,766,481 over the last quarter. Corporate insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on PCVX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday. Finally, The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research note on Friday, December 20th. They set a “buy” rating and a $135.00 target price on the stock. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.